Affiliated Cixi Hospital, Wenzhou Medical University, Zhejiang, China.
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Zhejiang, China.
Pharmacol Res. 2024 May;203:107185. doi: 10.1016/j.phrs.2024.107185. Epub 2024 Apr 12.
Microbes, including bacteria, viruses, fungi, and other eukaryotic organisms, are commonly present in multiple organs of the human body and contribute significantly to both physiological and pathological processes. Nowadays, the development of sequencing technology has revealed the presence and composition of the intratumoral microbiota, which includes Fusobacterium, Bifidobacteria, and Bacteroides, and has shed light on the significant involvement in the progression of colorectal cancer (CRC). Here, we summarized the current understanding of the intratumoral microbiota in CRC and outline the potential translational and clinical applications in the diagnosis, prevention, and treatment of CRC. We focused on reviewing the development of microbial therapies targeting the intratumoral microbiota to improve the efficacy and safety of chemotherapy and immunotherapy for CRC and to identify biomarkers for the diagnosis and prognosis of CRC. Finally, we emphasized the obstacles and potential solutions to translating the knowledge of the intratumoral microbiota into clinical practice.
微生物,包括细菌、病毒、真菌和其他真核生物,通常存在于人体的多个器官中,并对生理和病理过程都有重要贡献。如今,测序技术的发展揭示了肿瘤内微生物组的存在和组成,其中包括梭杆菌属、双歧杆菌属和拟杆菌属,并阐明了其在结直肠癌(CRC)进展中的重要作用。在这里,我们总结了目前对 CRC 肿瘤内微生物组的理解,并概述了其在 CRC 的诊断、预防和治疗中的潜在转化和临床应用。我们重点回顾了针对肿瘤内微生物组的微生物治疗的发展,以提高 CRC 化疗和免疫治疗的疗效和安全性,并确定 CRC 诊断和预后的生物标志物。最后,我们强调了将肿瘤内微生物组知识转化为临床实践的障碍和潜在解决方案。